We reveal that inhibiting CX3CR1 results in sensitization to platinum drugs, displayed by replication fork stalling, impaired cell cycle progression, unresolved cisplatin-DNA adducts, and loss of cancer cell viability upon platinum treatment. The gene discussed is CX3CR1; the disease is cancer.